Overcoming Microenvironmental Resistance to PD-1 Blockade in Genetically Engineered Lung Cancer Models

Investigators found that antiangiogenic treatment facilitated non–small cell lung cancer tumor infiltration by PD-1⁺ regulatory T cells, which were more efficiently targeted by the PD-1 antibody than CD8⁺ T cells.